El Septimo CEO ZAYA YOUNAN SECURES TWO U.S. PATENTS FOR BREAKTHROUGH CIGAR-COOLING TECHNOLOGY DESIGNED TO TRANSFORM THE CIGAR INDUSTRY

El Septimo CEO Zaya S. Younan secured U.S. Design Patent D1,064,394 and U.S. Utility Patent 12,564,216 for a cigar ashtray/cooling system intended to remove heat from lit cigars between puffs. The system targets an approximately 250°C thermal environment, near nicotine's reported 247°C boiling point, with the stated aim of preserving flavor while potentially reducing heat-driven pyrolysis and combustion byproducts. Health-risk and toxicant-reduction claims remain unvalidated, with independent laboratory and sensory testing identified as the next development stage.

Analysis

This is not investable public-equity news absent a listed parent, disclosed commercialization plan, or independently validated product data. The utility patent may create a niche licensing asset, but a design patent contributes little economic moat; practical enforceability will depend on claim breadth, alternative cooling designs, manufacturing cost, and whether consumers accept an accessory that changes the ritual of premium-cigar consumption.

The material second-order risk is regulatory rather than competitive. Health-adjacent marketing claims tied to reduced combustion byproducts, nicotine preservation, or cognitive benefits invite FDA/FTC scrutiny if commercial messaging gets ahead of controlled emissions testing. That scrutiny could raise launch costs, constrain distribution through tobacconists, and make larger tobacco companies unlikely licensees until third-party laboratory data establishes both repeatable temperature control and a meaningful toxicant reduction.

Near term, the relevant catalyst is publication of blinded, independent comparisons versus conventional smoking, including puff-by-puff temperature, CO, carbonyls, particulate matter, nicotine delivery, and sensory outcomes. Even favorable chemistry results would not establish reduced disease risk, and an adverse result—particularly reduced flavor or nicotine delivery—would undermine premium pricing. Over 6-18 months, validated sensory improvement could make the device more credible as a luxury accessory rather than a harm-reduction product, which is the more commercially defensible positioning.

Contrarian view: the claimed ~250°C target may be technically difficult to reconcile with a satisfying lit-cigar experience because combustion-zone temperatures are materially higher and smoke formation depends on heat gradients, airflow, and puff behavior. The addressable market is therefore likely premium accessory spend, not broad substitution within tobacco; headline patent value is likely overestimated until unit economics, retail adoption, and scientific replication are disclosed.

Key Decisions for Investors

• No trade: El Septimo/LGMYC appears privately held and the disclosed information provides no public-market instrument, revenue guidance, production capacity, or independent efficacy data.
• Create a 1-3 month event watch for independently commissioned laboratory results and FDA/FTC-facing marketing language. Treat reproducible reductions in CO/carbonyls without sensory degradation as a commercialization-positive signal; unsupported health claims or regulator action as immediate negative signals.
• For listed tobacco exposure, maintain existing views rather than repositioning in PM, MO, BTI, or TPB: a premium-cigar accessory has immaterial near-term volume or margin implications for these issuers. Reassess only if a major listed manufacturer/distributor announces a licensing, distribution, or acquisition agreement with disclosed economics.
• If a future listed vehicle or licensing counterparty emerges, require evidence of gross margin above 50%, repeat accessory sales, and retailer reorder rates before underwriting value; falsify the adoption thesis if independent testing fails to show a measurable thermal/sensory advantage or if regulatory restrictions prevent health-related differentiation.